NCT01974856
Completed
Not Applicable
A Prospective Observational Study of Clinical Outcomes for the NanoString® Technologies, Inc. Breast Cancer Intrinsic Subtype Test
ConditionsBreast Cancer
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Breast Cancer
- Sponsor
- NanoString Technologies, Inc.
- Enrollment
- 201
- Locations
- 2
- Primary Endpoint
- The proportion of patients whose choice of treatment is changed as a result of receiving the Prosigna test result.
- Status
- Completed
- Last Updated
- 10 years ago
Overview
Brief Summary
The primary objective of this study is to assess the extent to which the Prosigna™ Breast Cancer Prognostic Gene Signature Assay affects the medical oncologist's treatment recommendations regarding adjuvant chemotherapy and actual treatments received for patients with early-stage breast cancer.
Detailed Description
Changes in treatment recommendations will include (1) hormonal therapy alone, (2) hormonal therapy plus chemotherapy, and (3) changes in types of chemotherapy if chemotherapy was recommended before and after the test.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Resected node-negative, estrogen-receptor-positive, HER2-negative early- stage invasive breast cancer (T1-T2, N0, pN0 (i+), pN0 (mol+), M0)
- •Estrogen receptor status will be evaluated by Immunohistochemistry (IHC) and more than 1% of stained tumor cells will be considered positive.
- •HER2 status will be evaluated by IHC (0 or 1+, or 2+ will be considered negative) and by in-situ fluorescence hybridization.
- •Postmenopausal women defined as:
- •Natural Amenorrhea \> 12 months, regardless of age
- •Bilateral oophorectomy, regardless of age (the oophorectomy must have been carried out at least 4 weeks before entering the study)
- •Radiological castration with amenorrhea \> 3 months, regardless of age
- •Hysterectomy and postmenopausal blood levels
- •Able to give consent
- •Eligible for treatment of breast cancer with adjuvant chemotherapy
Exclusion Criteria
- •Tumor size T3-T4
- •Non-invasive breast cancer (e.g., Paget's disease, DCIS)
- •Tumors with nodes that are not N0, pN0 (i+), or pN0 (mol+)
- •Tumors that are estrogen-receptor negative or HER2 positive
- •Have metastatic disease
- •Unable to give informed consent
- •Unable to complete patient reported outcome surveys
- •Have contraindications for adjuvant chemotherapy
- •Age, performance status, significant comorbidities
- •ECOG performance status \> 1
Outcomes
Primary Outcomes
The proportion of patients whose choice of treatment is changed as a result of receiving the Prosigna test result.
Time Frame: 6 months
Study Sites (2)
Loading locations...
Similar Trials
Completed
Not Applicable
A Prospective Observational Study of Clinical Outcomes for the NanoString® Technologies Prosigna Gene Signature AssayBreast CancerNCT01899079NanoString Technologies, Inc.217
Recruiting
Not Applicable
Breast Cancer Patient Engagement With Patient Reported Outcome Measure SurveyBreast CancerNCT03995082University of Colorado, Denver925
Completed
Not Applicable
An Observational Study of Current Practice Pattern on the Treatment of Women With Metastatic Breast Cancer Whose Tumors Overexpress Her2neuBreast CancerNCT00153218Cancer Research Network94
Terminated
Not Applicable
A Prospective Study of Clinical Outcomes for the Pathwork Tissue of Origin TestNeoplasm MetastasisNCT01649453Cedar Associates LLC19
Completed
Not Applicable
Breast Cancer Pre-habilitation and Prospective Surveillance to Prevent, Detect, and Optimize Physical and FunctionBreast CancerNCT06081127Northwestern University75